Net Loss Per Share

3 Months Ended

Dec. 31, 2024

NET LOSS PER SHARE

The following table presents the computation of basic and diluted net loss per share.


	Three Months Ended December 31,
	2024		2023
	(in thousands, except per share amounts)
Numerator:
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	$	(173,085)	$	(132,864)

Denominator:
Weighted-average basic shares outstanding (1)	124,848		107,415
Effect of dilutive securities	—		—
Weighted-average diluted shares outstanding (1)	124,848		107,415

Basic net loss per share	$	(1.39)	$	(1.24)
Diluted net loss per share	$	(1.39)	$	(1.24)

(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of

diluted net loss per share because to include them would be anti-dilutive.